Prof. Francesco Lo Coco
1974-1981 Medicine Degree University of Pisa , Italy
1982-1985 Hematology Specialist Degree, University La Sapienza, Rome, Italy
1992-1994 Research Fellowship in Molecular Biology, Columbia University, New York,USA
1987-2002 University La Sapienza, Rome; Dept. of Hematology, Head Molecular Biology Lab.
1993-2002 University La Sapienza, Rome; Senior Staff Member, Hematology Section
2002-2005 University Tor Vergata, Rome; Associate Professor of Hematology
2005-present University Tor Vergata, Rome; Full Professor of Hematology
Selected Honors, Awards, Lectures
-International Prize G. Di Guglielmo, awarded by the Accademia Nazionale dei Lincei (1992)
-S. Goshe Memorial Oration, Institute of Hematology, Medical College, Kolkata (India) (2009)
-Commendatore al Merito della Repubblica Italiana (2013)
-Sapio Award for Italian Research (Health section, 2014)
-Tata Memorial Center Oration, Mumbay, India (2015)
-G. Venosta Prize, AIRC (2016)
-P. Stryckmans Memorial Lecture (Belgian Society of Hematology (2017)
2010-2013 Journal of Clinical Oncology (Editorial Board Member)
1996-2013 Leukemia (Editorial Board Member)
1994-present Haematologica (Editorial Board Member)
Scientific Societies & Research Organizations
2000-2002: President of the Italian Society of Experimental Hematology (SIES)
2001-2003: Health Research Commission, Italian Ministry of Health
2008-2013: Chairman of the Education Committee of European Hematology Association (EHA)
2008-2012: International Members Committee, American Society of Hematology (ASH)
2012-2015: Member of the Nominating Committee, American Society of Hematology (ASH)
2012- present: Member of the Scientific Committee, Fondazione Veronesi
2014-present: President of the Scientific Committee Associazione Italiana contro le Leucemie
401 peer-reviewed articles in journals covered by the JCR® and PubMed.
H-index: 89, Citations n. >34.000 (source: google scholar)
Our main scientific interest and research activities include genetic characterization, diagnostics, monitoring and treatment of hematologic tumors, particularly acute myeloid leukaemia (AML) and acute promyelocytic leukaemia (APL). Over the last 20 years, laboratory and clinical investigations in this field have significantly contributed to improve patient outcome and provided several important concepts with general implications in the therapy of leukemia and cancer. Using APL as a model, our group showed the clinical advantage of administering pre-emptive therapy for molecular relapse in leukemia, i.e. anticipating the delivery of salvage treatment at the time of MRD recurrence and prior to the occurrence of full-blown relapse.
A recent clinical study coordinated at Tor Vergata University demonstrated the efficacy of the first curative treatment for an acute leukemia that does not include chemotherapy, providing a paradigm of the benefit targeted therapies in acute leukemias. Research on AML is mainly focused on MRD and clonal evolution as well as on the identification of new genetic lesions and targeted therapies.